Industry News
Psychiatric Times
Dr. Elizabeth Wassenaar is featured in this Psychiatric Times article examining the comorbidity of eating disorders and addiction and the potential impact and complexity of using GLP-1 agonist medications in treatment. In the article, Dr. Wassenaar shares concerns about using GLP-1As and their impact on the eating disorder community:
"GLP-1 receptor agonists work in the brain to suppress appetite and increase feelings of fullness, which is how they act for individuals who take them to manage their type 2 diabetes. We are beginning to notice patients who are vulnerable to disordered eating and/or relapse of their eating disorder following the initiation of GLP-1 receptor agonist medications."